Tech Company Financing Transactions

Catamaran Bio Funding Round

Catamaran Bio secured a $42 million Series A funding round on 11/24/2020. Backers included Lightstone Ventures, Sofinnova Ventures and Astellas Venture Capital.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

610 Main St.
Cambridge, MA 02139
USA

Phone

Undisclosed

Website

www.catamaranbio.com

Email Address

[email protected]

Overview

Catamaran is developing transformative off-the-shelf CAR-NK cell therapies. We are driven to realize the full potential of cell therapy by powering a key type of immune cell, Natural Killer (NK) cells, with new properties to create transformative cancer treatments for more patients.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Kevin Pojasek

        

Chief Medical Officer

Chris Carpenter

        

Chief Operating Officer

Mark Boshar

        

Chief Scientific Officer

Vipin Suri

        

VP - Bus. Development

Bharat Reddy

        

VP - R & D

Celeste Richardson

        

Browse more venture capital transactions:

Prev: 11/24/2020: GT Medical Technologies venture capital transaction
Next: 11/24/2020: Friday.app venture capital transaction

Share this article

About Database of VC Transactions

We report on funding rounds that are announced publicly. All VC database entries on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary